Krista Lanctot



Sunnybrook Health Sciences Centre
2075 Bayview Avenue, FG21A, Toronto, Ontario Canada M4N 3M5
Research Interests
clinical pharmacology, neuropharmacology, Pharmacoeconomics, psychopharmacology
Appointment Status
TBC - Contact faculty member for details

Dr. Krista Lanctôt’s research goal is to optimize treatment for neuropsychiatric symptoms including cognitive changes, apathy, agitation, and mood changes in those with dementia, or at risk for dementia. Her research addresses these goals by determining the underlying neurobiology of neuropsychiatric symptoms, examining predictors of treatment response, and using novel or repurposed pharmacological treatments. The research team also investigates neurostimulation, exercise and dietary interventions in combination with medications. A variety of tools including neuroimaging, serum biomarkers, and neuropsychiatric assessments are used in combination with clinical trials. This research will contribute to our understanding of the link between neuropsychiatric symptoms and biomarkers, which in turn can identifying treatment targets and promote precision medicine. 

Publications (student names bolded):

Chen JJ, Thiyagarajah M, Song J, Chen C, Herrmann N, Gallagher D, Rapoport MJ, Black SE, Ramirez J, Andreazza AC, Oh P, Marzolini S, Graham SJ, Lanctôt KL. Altered central and blood glutathione in Alzheimer’s disease and mild cognitive impairment: a meta-analysis. Alzheimers Res Ther. 2022 Feb 5;14(1):23. doi: 10.1186/s13195-022-00961-5.PMID: 35123548

Azhar L, Kusumo RW, Marotta G, Lanctôt KL, Herrmann N. Pharmacological Management of Apathy in Dementia. CNS Drugs. 2022 Feb;36(2):143-165. doi: 10.1007/s40263-021-00883-0. Epub 2022 Jan 10. PMID: 35006557 Review

Tumati S, Lanctôt KL, Wang R, Li A, Davis A, Herrmann N. Medical cannabis use in older adults in Canada: self-reported data on types, amount, and perceived effects.  Drugs Aging. 2022 Feb;39(2):153-163. doi: 10.1007/s40266-021-00913-y. Epub 2021 Dec 23. PMID: 34940961 (top 5 downloads Jan to Jun 2022)

Feng V, Tumati S, Wang R, Bawa KK, Gallagher D, Herrmann N, Marzolini S, Oh P, Andreazza A, Lanctôt KL. The relationship between oxidative stress and subjective sleep quality in people with coronary artery disease. Brain Sci. 2022 Aug 12;12(8):1070. doi: 10.3390/brainsci12081070. PMID: 36009133  corresponding author

Bawa KK, Ba J, Kiss A, Wang R, Feng V, Swardfager W, Andreazza A, Gallagher D, Marotta G, Herrmann N, Lanctôt KL. Lipid peroxidation as a marker of apathy and executive dysfunction in patients at risk for vascular cognitive impairment. J Alzheimers Dis. 2022 Sep;89(2):733-743. doi: 10.3233/JAD-220274 PMID: 3593824

Herrmann N, Wang HJ, Song BX, Bawa KK, Lanctôt KL. Risks and benefits of current and novel drugs to treat agitation in Alzheimer’s disease. Expert Opin Drug Saf. 2022 Oct;21(10):1289-1301. doi: 10.1080/14740338.2022.2136162. Epub 2022 Oct 20. PMID: 36252087

Ruthirakuhan M, Ismail Z, Herrmann N, Gallagher D, Lanctôt KL. Mild behavioral impairment is associated with progression to Alzheimer’s disease: results from a clinico-pathological study. Alzheimers Dement. 2022 2022 Nov;18(11):2199-2208. doi: 10.1002/alz.12519. Epub 2022 Feb 1. PMID: 35103400

Ruthirakuhan M, Cogo-Moreira H, Swardfager WL, Herrmann N, Lanctôt KL, Black SE. Cardiovascular risk factors and risk of Alzheimer's disease and mortality: a latent class approach. J Am Heart Assoc. 2023 Jan 3;12(1):e025724. doi: 10.1161/JAHA.122.025724. Epub 2022 Dec 24. PMID: 36565204

Lanctôt KL, Ismail Z, Bawa KK, Cummings J, Husain M, Mortby ME, Robert P. Distinguishing apathy from depression: a review differentiating the behavioral, neuroanatomic, and treatment-related aspects of apathy from depression in neurocognitive disorders. Int J Geriatr Psychiatry. 2023 Feb;38(2):e5882. doi: 10.1002/gps.5882. PMID: 36739588 Review

Koo GK*, Gaur A*, Tumati S, Kusumo RW, Bawa KK, Herrmann N, Gallagher D, Lanctôt KL. Identifying factors influencing cognitive outcomes after anodal transcranial direct current stimulation in older adults with and without cognitive impairment: a systematic review. Neurosci Biobehav Rev. 2023 Mar;146:105047. doi: 10.1016/j.neubiorev.2023.105047. Epub 2023 Jan 14.PMID: 36646259 Review. PMID: 36646259 Review. *equal contributors

Chinna-Meyyappan A, Wang HJ, Bawa KK, Ellazar E, Norris-Roozmon E, Naglie G, Herrmann N, Charlton JL, Koppel S, Castel S, Lanctôt KL, Rapoport MJ. Risk of motor vehicle collisions and culpability among older drivers using cannabis: a meta-analysis. Brain Sci. 2023 Feb 28;13(3):421. doi: 10.3390/brainsci13030421 PMID: 36979231

Kim D, Kiss A, Bronskill SE, Lanctôt KL, Herrmann N, Gallagher D. Association between depression, gender and Alzheimer’s neuropathology in older adults without dementia. Int J Geriatr Psychiatry 2022 Aug 25;37(10). doi: 10.1002/gps.5809. Online ahead of print. PMID: 36047339

Lanctôt KL, Chen C, Mah E, Kiss A, Li A, Shade D, Scherer RW, Vieira D, Coulibaly H, Rosenberg PB, Lerner AJ, Padala PR, Brawman-Mintzer O, van Dyck CH, Porsteinsson AP, Craft S, Levey A, Burke WJ, Mintzer J, Herrmann N. Cost consequence analysis of Apathy in Dementia Methylphenidate Trial 2 (ADMET 2). Int Psychogeriatr. 2023 Apr 17:1-9. doi: 10.1017/S1041610223000327. Online ahead of print. PMID: 37066690